Evidence map›Paper›PMID 27056073›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2016

Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms.

Rashmi S Goswami, Sa A Wang, Courtney DiNardo, Zhenya Tang, Yan Li, Wenli Zuo, Shimin Hu, Shaoying Li, L Jeffrey Medeiros, Guilin Tang

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences.Mediterranean journal of hematology and infectious diseases · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Rashmi S GoswamiDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sa A WangDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Courtney DiNardoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhenya TangDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yan LiDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wenli ZuoDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shimin HuDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shaoying LiDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L Jeffrey MedeirosDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guilin TangDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USUniversity Health Network · CA

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Deletion 7q is a common chromosomal abnormality in myeloid neoplasms. Detection of del(7q) in patients following cytotoxic therapies is highly suggestive of an emerging therapy-related myeloid neoplasm. In this study, we describe 39 patients who acquired del(7q) as a sole abnormality in their bone marrow following cytotoxic therapies for malignant neoplasms. The median interval from cytotoxic therapies to detection of del(7q) was 40 months (range, 4-190 months). Twenty-eight patients showed an interstitial and 11 showed a terminal 7q deletion. Fifteen patients (38%) had del(7q) as a large clone and 24 (62%) as a small clone. With a median follow-up of 21 months (range, 1-135 months), 18 (46%) patients developed therapy-related myeloid neoplasms, including all 15 patients with a large del(7q) clone and 3/24 (12.5%) with a small clone. Of the remaining 21 patients with a small del(7q) clone, 16 showed no evidence of therapy-related myeloid neoplasms and 5 had an inconclusive pathological diagnosis. We conclude that isolated del(7q) emerging in patients after cytotoxic therapy may not always be associated with therapy-related myeloid neoplasms in about half of patients. The clone size of del(7q) is critical; a large clone is almost always associated with therapy-related myeloid neoplasms, whereas a small clone can be a clinically indolent or transient finding.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 7AdultAgedAged, 80 and overAntineoplastic AgentsDatabases, GeneticFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesNeoplasms, Second PrimaryAntineoplastic Agents

Identifiers

PMID27056073
OpenAlexW2333006871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.